| Literature DB >> 30125454 |
Mikel Byrne1, Ben Archibald-Heeren1,2, Yunfei Hu3,2, Andrew Fong1, Leena Chong1, Amy Teh1,3,4.
Abstract
Radiotherapy to the breast after surgery sometimes requires adjoining nodes to be included in the treatment volume. In these cases, the traditional approach has been a complex 3-Dimensional Conformal Radiotherapy (3DCRT) beam arrangement which can result in significant dose heterogeneity at the beam junctions. A Volumetric Modulated Arc Therapy (VMAT) beam arrangement has previously been proposed for breast cases, where the chest wall/breast is treated with a limited angle (partial arc) tangential VMAT technique (Virén et al. [2015] Radiat Oncol. 10:79). In our study, this approach is extended to breast and chest wall cases with adjoining nodes by adding a separate conventional VMAT arc field specifically limited to the superior nodes. This VMAT method was implemented using a semiautomated approach on 27 patients, and the resultant plan compared to a monoisocentric 3DCRT plan. Plan statistics, Dose-Volume Histogram (DVH) analysis and Radiation Oncologist (RO) preference were assessed. When compared to the 3DCRT technique, the VMAT planning method was found to result in better target volume coverage, high doses to organs at risk (OAR) were reduced but greater OAR volumes received low doses. Having said that, the volume receiving low doses with this tangential VMAT technique was less than that of other VMAT planning methods described in the literature, and the integral dose was less than the 3DCRT method. The VMAT technique also resulted in more robust junction doses that the 3DCRT method. RO review found that the VMAT technique was preferred in 81% of cases. Specifically, the VMAT plans were preferred in all categories of patients except left chest wall cases where the intermammary nodes were also treated. The VMAT technique described here is a useful addition to the treatment options available for breast/chest wall and nodal patients.Entities:
Keywords: zzm321990VMATzzm321990; breast; nodes; optimization; tangential
Mesh:
Year: 2018 PMID: 30125454 PMCID: PMC6123166 DOI: 10.1002/acm2.12442
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Figure 1Schematic illustration of an example of the VMAT arc gantry ranges used for a right breast case. The arcs are separated longitudinally with the four short arcs (orange) only used to treat the breast/chest wall and IM PTVs and junction region, while the longer arcs (yellow) are used for the AX and SC PTVs and junction region. The nominal tangent angle determined by the script is shown as a light gray line.
The DVH parameters used in the VMAT planning based on RTOG 1304 clinical trial for different regions of interest (ROI).25
| ROI | Plan metric | Acceptable value | Ideal value |
|---|---|---|---|
| Target volume coverage and dose homogeneity | |||
| PTV Breast/Chest wall | V90 (V45 Gy) | >90% | >99% |
| PTV Breast/Chest wall | D95 | >90% | >95% |
| PTV Breast/Chest wall | D0.3 cc | <120% | <115% |
| PTV IM | V90 (V45 Gy) | >90% | >99% |
| PTV IM | D95 | >90% | >95% |
| PTV IM | D0.03 cc | <115% | <110% |
| PTV AX | V90 (V45 Gy) | >90% | >99% |
| PTV AX | D95 | >90% | >95% |
| PTV AX | D0.03 cc | <115% | <110% |
| PTV SC | V90 (V45 Gy) | >90% | >99% |
| PTV SC | D95 | >90% | >95% |
| PTV SC | D0.03 cc | <115% | <110% |
| External | D0.03 cc | <120% | <110% |
| Organs at risk dose constraints | |||
| Lung (Ipsilateral) | V20 Gy | <35% | <15% |
| Lung (Ipsilateral) | V10 Gy | <60% | <50% |
| Lung (Ipsilateral) | V5 Gy | <70% | <65% |
| Lung (Contralateral) | V5 Gy | <15% | <10% |
| Heart | Mean dose | <500 cGy | <400 cGy |
| Heart | V25 Gy | <10% | <5% |
| Heart | V15 Gy | <15% | <10% |
| Heart | D0.03 cc | <3000 cGy | <2500 cGy |
| Contralateral breast | D0.03 cc | <1000 cGy | <300 cGy |
| Contralateral breast | D5 | <410 cGy | <300 cGy |
| Spinal cord | D0.03 cc | <4500 cGy | <4000 cGy |
Target volume coverage and OAR dose metrics achieved for 3DCRT and VMAT planning methods
| ROI | Plan metric | 3DCRT | VMAT | Superior technique | Accept or reject H0 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pseudo‐median (Hodges‐Lehmann) | 95% confidence interval | Clinical goal | Pseudo‐median (Hodges‐Lehmann) | 95% confidence interval | Clinical goal | ||||
| Target volume coverage and dose homogeneity | |||||||||
| PTV breast/chest wall | V90 (V45 Gy) | 98.1% | (87.5%–99.8%) | Acceptable | 99.3% | (97.2%–99.9%) | Ideal | VMAT | Reject |
| PTV breast/chest wall | D95 | 93.6% | (77.5%–96.9%) | Acceptable | 96.5% | (93.1%–98.6%) | Ideal | VMAT | Reject |
| PTV breast/chest wall | D0.3 cc | 109.9% | (106.3%–122.9%) | Ideal | 108.4% | (107.3%–111.1%) | Ideal | VMAT | Reject |
| PTV breast/chest wall | V105 (V52.5 Gy) | 11.0% | (1.1%–25.8%) | NA | 12.5% | (7.3%–22%) | NA | 3DCRT | Accept |
| PTV IM | V90 (V45 Gy) | 92.3% | (51.5%–99.2%) | Acceptable | 96.8% | (89.2%–98.3%) | Acceptable | VMAT | Accept |
| PTV IM | D95 | 89.3% | (36.3%–93.7%) | Fail | 92.8% | (84.1%–94.5%) | Acceptable | VMAT | Accept |
| PTV IM | D0.03 cc | 106.6% | (101.1%–111%) | Ideal | 108.3% | (107.6%–109.7%) | Ideal | 3DCRT | Accept |
| PTV AX | V90 (V45 Gy) | 98.0% | (94.8%–100%) | Acceptable | 99.7% | (99.1%–100%) | Ideal | VMAT | Accept |
| PTV AX | D95 | 94.0% | (89.8%–98.7%) | Acceptable | 97.5% | (95.8%–99.4%) | Ideal | VMAT | Reject |
| PTV AX | D0.03 cc | 107.1% | (104.8%–110.7%) | Ideal | 108.0% | (107.1%–109.1%) | Ideal | 3DCRT | Accept |
| PTV SC | V90 (V45 Gy) | 98.3% | (78.4%–100%) | Acceptable | 99.9% | (98.9%–100%) | Ideal | VMAT | Reject |
| PTV SC | D95 | 93.4% | (55.2%–97.8%) | Acceptable | 98.0% | (95.2%–99.3%) | Ideal | VMAT | Reject |
| PTV SC | D0.03 cc | 104.8% | (102.2%–109.8%) | Ideal | 107.6% | (106.6%–109.1%) | Ideal | 3DCRT | Reject |
| External | D0.03 cc | 110.3% | (106.6%–122.9%) | Acceptable | 108.6% | (107.4%–111.9%) | Ideal | VMAT | Reject |
| Organs at risk dose constraints | |||||||||
| External | V5 Gy (cc) | 4509.3 | (2691.8–6596.9) | NA | 5444.7 | (3432.8–7483.6) | NA | 3DCRT | Reject |
| External | Dintegral (Gy x L) | 176.1 | (107.7–259.1) | NA | 165.8 | (97.6–232.4) | NA | VMAT | Reject |
| Lung (Ipsilateral) | V20 Gy | 27.2% | (15.7%–42%) | Acceptable | 22.3% | (15%–33.9%) | Acceptable | VMAT | Reject |
| Lung (Ipsilateral) | V10 Gy | 35.2% | (20.5%–48.8%) | Ideal | 37.4% | (24%–50.2%) | Ideal | 3DCRT | Accept |
| Lung (Ipsilateral) | V5 Gy | 46.0% | (28.9%–59.9%) | Ideal | 55.5% | (38.9%–67%) | Ideal | 3DCRT | Reject |
| Lung (Contralateral) | V5 Gy | 0.0% | (0%–0.6%) | Ideal | 2.0% | (0%–8.1%) | Ideal | 3DCRT | Reject |
| Heart | Mean dose (cGy) | 100.9 | (42.8–401.7) | Ideal | 192.2 | (90.5–592.0) | Ideal | 3DCRT | Reject |
| Heart | V25 Gy | 0.1% | (0%–4.8%) | Ideal | 0.0% | (0%–4.4%) | Ideal | VMAT | Accept |
| Heart | V15 Gy | 0.3% | (0%–7.2%) | Ideal | 0.2% | (0%–10.1%) | Ideal | VMAT | Accept |
| Heart | D0.03 cc (cGy) | 1176.4 | (375.3–3206.9) | Ideal | 1255.4 | (518.1–2408.2) | Ideal | 3DCRT | Accept |
| Contralateral breast | D0.03 cc (cGy) | 872.8 | (204.6–4719.6) | Acceptable | 848.1 | (379.8–1756.7) | Acceptable | VMAT | Accept |
| Contralateral breast | D5 | 130.4 | (62.2–334.5) | Ideal | 309.0 | (163.7–515.0) | Acceptable | 3DCRT | Reject |
| Spinal cord | D0.03 cc (cGy) | 1339.4 | (147.4–3872.1) | Ideal | 1456.0 | (467.6–2570.4) | Ideal | 3DCRT | Accept |
Figure 2The median DVH for both 3DCRT and VMAT planning methods shown for selected regions of interests with interquartile ranges as dashed lines.
Comparison of common low‐dose metrics for a range of VMAT studies. Laterality indicated in brackets refers to the treatment plan. 1Bowan et al. report on several different arc ranges but metrics for the 240° dual arc without arc splitting (NS240) are reported, as this arrangement was generally the best for contralateral lung and contralateral breast
| Study | Patient cohort | Plan method | Number of patients | Prescription (Gy) | Low‐dose metric | ||||
|---|---|---|---|---|---|---|---|---|---|
| External V5 Gy (cc) | Lung (Contralateral) mean dose (Gy) | Lung (Contralateral) V5 Gy (%) | Heart mean dose (Gy) | Contralateral breast mean dose (Gy) | |||||
| Present study | Lt and Rt + various nodes | As described | 27 | 50 | 5444 | 0.9 | 2.4 | 2.4 | 1.1 |
| Present study (only Lt patients) | Lt + various nodes | As described | 8 | 50 | 6057 | 1.0 | 3.7 | 5.3 | 1.5 |
| Tyran et al. | Lt + all nodes | 240° (dual) | 10 | 50 | 4.0 | 15.0 | 8.6 | 3.2 | |
| Boman et al. | Lt and Rt + various nodes | 240° (dual)¹ | 19 | 50 | 9534 | 3.9 (Lt), 2.6 (Rt) | 24.1 (Lt), 5.4 (Rt) | 7.7 (Lt), 4.6 (Rt) | 4.1 |
| Badakhshi et al. | Lt and Rt + SC nodes in 4 cases | 360° | 12 | 50 | 5.6 (Lt) | 19.5 | 12.4 (Lt) | ||
| Johansen et al. | Lt and Rt + all nodes | 361° | 8 | 50 | 2.9 | 4.6 | 2.0 | ||
| Pasler et al. | Lt breast + SC nodes | Approx. 250° (single) | 10 | 50 | 3.4 | 23.0 | 8.9 | 2.8 | |
Indicates that these data were used in single sample t test comparison to the present study.
Figure 3Comparison of typical dose distributions seen from multiple planning methods for a chest wall case with IM, SC and AX nodes. On the left is the clinical 3DCRT plan, in the middle is the tangential VMAT plan, and on the right is a full arc VMAT plan. The lowest isodose line displayed (purple) is 5 Gy to highlight the differences in the volume covered by this isodose.
Figure 4Dose contribution across junction region between breast/chest wall and AX/SC nodes from respective beams/arcs for 3DCRT and VMAT plans for an example case.
Figure 5Dose change across junction region with 3 mm longitudinal shift of SC/AX beams relative to the breast/chest wall beams for 3DCRT and VMAT plans for an example case.